Advanced autoclave technology supports pioneering genetic research at Oxford Science Park
Nucleome Therapeutics, a leading UK biotech firm that specialises in decoding the dark genome's non-coding DNA regions to develop precision medicines for autoimmune diseases like multiple sclerosis, lupus, and rheumatoid arthritis, purchase LTE research-grade autoclave to assist with research. Click to read more...
United Kingdom Anthony Campbell Carr Paul Brackstone Oxford University Bioescalator Oxford Science Enterprises Nucleome Therapeutics
Source: labmate-online.com